AUPH (77) PHVS (59) RCUS (19) HCM (42) ⌘ Pro Terminal →

Prestige Consumer Healthcare Inc. (PBH) — RQD Stock Rating Cockpit

$48.75 +2.01% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $48.83

Prestige Consumer Healthcare Inc. (PBH) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 60/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.4% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $2.31B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PBH Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PBH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Prestige Consumer Healthcare Inc. (NYSE: PBH) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $48.75 (+2.01% 1D, market cap $2.31B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, PBH ranks #174 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PBH compare to AUPH and PHVS in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBH carries a Roarable C- (60/100 RQD), trailing P/E of 12.1x, gross margin of 54.7%, and ROIC of 13.8%. By comparison, AUPH (Aurinia Pharmaceuticals Inc) holds a B+ grade (77/100 RQD, P/E 8.0x, ROIC 16.5%, cap $2.29B) and PHVS (Pharvaris N.V.) posts a C- grade (59/100 RQD, P/E N/A, ROIC —, cap $2.34B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while AUPH leads on capital efficiency (16.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PBH?

▼

Per PBH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001295947), Prestige Consumer Healthcare Inc. generated $1.09B in revenue (-4.3% YoY), $190.3M in net income, and $246.4M in free cash flow against $3.49B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $48.83 (+0.17%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 22.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 60/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.4% avg 90D alpha vs SPY • 53.5% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE+0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PBH)Realized 20D OHLCV Swing Band: ±6.2%

Deterministic 5-Pillar Attribution (60/100 Composite)

🔍 WHY PBH SCORES 60/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (28% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+14/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 22.6% FCF Margin ($246.4M FCF) & 54.7% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$49.00+1.4% Next Q

Q2 (-2Q)

Grade C+$49.71-3.1% Next Q

Q3 (-1Q)

Grade C+$48.15+1.2% Next Q

Current

Grade C-$48.75+0.4% Hist 90D α

Trajectory: B- (68) → C- (60)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PBH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 60/100 (C-) score, PBH faces multiple-compression risk if 12.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 52.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($48.48) or 200D SMA ($54.00) invalidates the momentum regime and cuts Target Base ($49.19) toward Bear Floor ($38.37).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PBH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PBH Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 60%NO 40%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

52.530 Oversold · 70 Hot

ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)

2.21>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

6 / 99-Pt Accounting

52-WEEK LASER RANGE22% OF RANGE

L: $43$48.75H: $71

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (55% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: B-RQD 14 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C-RQD 24 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on PBH

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (70)

13.8% ROIC with 54.7% gross margin and 10.67% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (55)

Altman-Z 2.21 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (58)

24/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like PBH

✓Company leadership has skin in the game with net positive insider conviction.

Bear Case: What Could Go Wrong

!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (PBH Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PBH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.86%⚡ TESTING RESISTANCE

2026-11-02O $47.79H $48.75L $47.79C $48.75VOL 343.4K

RES: $49.58SUP: $44.62SMA50: $48.48SMA200: $54.00

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PBH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PBH Butterfly Map → + Track PBH →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

2.7%/yr Implied 5Y Growth

vs. -4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PBH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PBH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PBH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PBH)

Health Care Rank #174 of 1016 ⚔️ AUPH vs PBH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PBH vs. AUPH, PHVS, RCUS, HCM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Prestige Consumer Healthcare Inc. (PBH) ranks #174 by composite RQD confidence (60/100, grade C-) and #236 by equity capitalization ($2.31B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while AUPH leads on capital efficiency and profitability with 16.5% ROIC and 88.5% gross margin. AUPH currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with PBH at 60/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PBH ACTIVE Prestige Consumer Healthcare Inc.	C-	60/100	12.1x	54.7%	13.8%	+2.01%	$2.31B	Benchmark Subject
AUPH Aurinia Pharmaceuticals Inc	B+	77/100	8.0x	88.5%	16.5%	-0.86%	$2.29B	/auph-vs-pbh →
PHVS Pharvaris N.V.	C-	59/100	—	—	—	+2.32%	$2.34B	/phvs-vs-pbh →
RCUS Arcus Biosciences Inc.	E	19/100	—	—	-35.0%	+1.20%	$2.37B	/rcus-vs-pbh →
HCM HUTCHMED (China) Limited	D-	42/100	5.2x	—	-2.5%	+2.03%	$2.37B	/hcm-vs-pbh →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001295947

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Prestige Consumer Healthcare Inc. (PBH) reported GAAP revenue of $1.09B (-4.3% vs. FY2024 revenue of $1.14B , and -3.3% cumulative change since FY2023) , GAAP net income of $190.3M, operating cash flow of $257.6M, and free cash flow of $246.4M (+1.3% YoY). On the balance sheet, PBH closed FY2025 with $3.49B in total assets against $0 in total debt (Altman Z-Score: 2.21, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-31	$1.09B	$190.3M	$257.6M	$246.4M	$3.49B	—
FY2024 (FY)	2025-03-31	$1.14B	$214.6M	$251.5M	$243.3M	$3.33B	$1.00B
FY2023 (FY)	2024-03-31	$1.13B	$209.3M	$248.9M	$248.9M	—	—

3. PBH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PBH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PBH compare to AUPH and PHVS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PBH?

Where is PBH trading relative to its 50-day, 200-day, and 52-week technical levels?

PBH last traded at $48.75 (+2.01% on volume of 343,426 shares), positioning the stock +0.56% above its 50-day simple moving average ($48.48) and -9.72% below its 200-day simple moving average ($54.00). Across its 52-week range of $42.62 to $71.07, PBH sits at the 21.5% percentile with a 14-day RSI of 52.5 (NEUTRAL RANGE) and an implied next-earnings move of ±6.2% ($45.73 to $51.77).

PBH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell PBH stock right now?

Prestige Consumer Healthcare Inc. (PBH) currently earns a Roarable Rating of C- (Hold — HOLD) with 60/100 RQD Confidence. Solid 55% profit margin (14% return on capital), mixed timing at 12x P/E—hold if owned, no rush to chase.

What is PBH's 12-month price target and RQD AI Jury consensus?

PBH's 12-month base price target is $49.19 (range $38.37 to $74.62), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PBH RQD Cockpit PBH 12M Forecast PBH Earnings & Move PBH Dividends & DRIP PBH Insiders & 13F PBH Whale Options PBH Profit Sankey PBH News & Why